Company Analysis
Sign in

Coherus Oncology, Inc. (CHRS)

Nasdaq: CHRS · Biological Products, (No Diagnostic Substances) · Redwood City, CA · filing with the SEC since 2011
Full chart Alerts Compare
Grade4.8
◀ Past 3.5● Present 5.6▶ Future 5.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

89 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Coherus Oncology, Inc.’s names, not what it holds today.

Patents granted
89
89 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 5 in 2023
Applications published
136
3 of them in 2025
Names they are printed under
4
a former name, a subsidiary
By yearGrantedApplications published
'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals25
Biotechnology5
Handling1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Coherus BioSciences, Inc. a former name
US, as the owner printed on each patent
76 granted
63 published
Coherus Biosciences, Inc. a former name
named as the applicant on its applications, in US
0 granted
43 published
SURFACE ONCOLOGY, LLC a subsidiary
US, as the owner printed on each patent. 2 more under the same name are not counted (printed in GB)
13 granted
13 published
Surface Oncology, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
17 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 15, 202512,358,978Anti-IL-27 antibodies and uses thereofBiotechnologySURFACE ONCOLOGY, LLC
Dec 10, 202412,162,941Anti-CD112R compositions and methodsPharmaceuticalsSURFACE ONCOLOGY, LLC
Sep 12, 202311,752,225Systems and methods for producing sterile injection devicesHandlingCoherus BioSciences, Inc.
Jun 6, 202311,667,702Stable aqueous formulations of afliberceptPharmaceuticalsCoherus BioSciences, Inc.
May 23, 202311,655,303Anti-CD39 antibody compositions and methodsPharmaceuticalsSURFACE ONCOLOGY, LLC
Feb 21, 202311,583,584Stable protein compositions and methods of their usePharmaceuticalsCoherus BioSciences, Inc.
Feb 14, 202311,576,971Method of filling a container with no headspacePharmaceuticalsCoherus BioSciences, Inc.
Aug 30, 202211,426,446Stable aqueous formulations of afliberceptPharmaceuticalsCoherus BioSciences, Inc.
Aug 2, 202211,400,072Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophyPharmaceuticalsCoherus BioSciences, Inc.
Jul 26, 202211,396,540Methods for making recombinant proteinsBiotechnologyCoherus BioSciences, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 19, 20252025/0197500METHODS OF TREATING CANCERBiotechnologyCoherus Biosciences, Inc.
May 15, 20252025/0154244ANTI-IL-27 ANTIBODIES AND USES THEREOFPharmaceuticalsSURFACE ONCOLOGY, LLC
Feb 13, 20252025/0051449Anti-CD112R Compositions and MethodsPharmaceuticalsSURFACE ONCOLOGY, LLC
Aug 22, 20242024/0279342COMPOSITIONS AND METHODS FOR IMMUNOTHERAPYPharmaceuticalsSurface Oncology, Inc.
Jun 20, 20242024/0199732Anti-IL-27 Antibodies and Uses ThereofBiotechnologySURFACE ONCOLOGY, LLC
Mar 21, 20242024/0092883METHODS OF PURIFYING RANIBIZUMAB OR A RANIBIZUMAB VARIANTBiotechnologyCoherus BioSciences, Inc.
Feb 29, 20242024/0066020COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)PharmaceuticalsCoherus Biosciences, Inc.
Jan 25, 20242024/0026001USE OF ANTI-IL-27 ANTIBODIESPharmaceuticalsSurface Oncology, Inc.
Jan 25, 20242024/0025987USE OF ANTI-IL-27 ANTIBODIESPharmaceuticalsSurface Oncology, Inc.
Dec 28, 20232023/0414800SYSTEMS AND METHODS FOR PRODUCING STERILE INJECTION DEVICESHandlingCoherus BioSciences, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 6 · Biotechnology 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CHRS · research, not advice